Skip to main content

Table 1 Occurrence rate of thrombus (efficacy endpoint)

From: Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery

Efficacy endpoint

Rivaroxaban group (case number/total number)

Parnaparin group (case number/total number)

P value

Primary efficacy endpoint

6/341 (1.7 %)

10/324 (3.1 %)

>0.25

Death

0/341 (0.0 %)

1/324 (0.3 %)

 

Non-fatal pulmonary embolism

1/341 (0.3 %)

1/324 (0.3 %)

 

DVT

6/341 (1.7 %)

8/324 (2.5 %)

 

Proximal end

2/341 (0.6 %)

3/324 (0.9 %)

 

Distal end only

4/341 (1.2 %)

5/324 (1.5 %)

 

Severe VTEa

2/341 (0.6 %)

4/324 (1.2 %)

>0.25*

Symptomatic VTEb

3/341 (0.9 %)

6/324 (1.9 %)

>0.25*

During the treatment

3/341 (0.9 %)

5/324 (1.5 %)

 

During the follow-up

0/277 (0.0 %)

1/268 (0.4 %)

 

Death during the follow-up

0/277 (0.0 %)

0/268 (0.0 %)

 
  1. *Used the corrected χ 2 test
  2. aSevere VTE was the combined turnover, composing of proximal DVT formation, nonfatal pulmonary embolism, and VTE-induced death
  3. bSymptomatic VTE included any symptomatic DVT formation (proximal or distal) and nonfatal/fatal symptomatic pulmonary embolism
Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X